Epidemiology, clinical manifestations, and outcome of mucormycosis in solid organ transplant recipients: a systematic review of reported cases

Emanuele Palomba,Marta Colaneri,Cecilia Azzarà,Marco Fava,Angelo Maccaro,Giulia Renisi,Giulia Viero,Harsimran Kaur,Arunaloke Chakrabarti,Andrea Gori,Andrea Lombardi,Alessandra Bandera

DOI: https://doi.org/10.1093/ofid/ofae043

2024-01-30

Open Forum Infectious Diseases

Abstract:Abstract Mucormycosis is an emerging disease primarily affecting the immunocompromised host, but scarce evidence is available for solid organ transplant recipients (SOTR). We systematically reviewed 183 cases occurring in SOTR, exploring epidemiology, clinical characteristics, causative pathogens, therapeutic approaches, and outcomes. Kidney transplants accounted for half of the cases, followed by heart (18.6%), liver (16.9%) and lung (10.4%). Diagnosis showed a dichotomous distribution, with 63.7% of cases reported within 100 days of transplantation and 20.6% occurring at least one year after transplant. The 90-day and 1-year mortality rates were 36.3% and 63.4%, respectively. Disseminated disease had the highest mortality at both time points (75% and 93%). Treatment with more than three immunosuppressive drugs showed a significant impact on 90-day mortality (OR 2.33, 95%CI 1.02-5.66; p=0.0493), as did a disseminated disease manifestation (OR 8.23, 95%, CI 2.20-36.71; p=0.0027) and the presence of diabetes (OR 2.35, 95%, CI 1.01-5.65; p=0.0497). Notably, prophylaxis was administered to twelve cases with amphotericin B. Further investigations are needed to validate these findings and to evaluate the potential implementation of prophylactic regimens in high-risk SOTR.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is a systematic review of the epidemiological characteristics, clinical manifestations, pathogenic microorganisms, treatment methods and prognosis of mucormycosis in solid organ transplant recipients (SOTR). Specifically, the research aims to explore the following aspects:

1. **Epidemiological characteristics**: Analyze the distribution of mucormycosis in different types of solid organ transplant recipients, such as kidney, heart, liver and lung transplant recipients.
2. **Clinical manifestations**: Describe the clinical features of mucormycosis in SOTR, including the forms of the disease (such as pulmonary infection, rhino - orbital - cerebral infection, skin infection or disseminated disease).
3. **Pathogenic microorganisms**: Determine the main types of microorganisms that cause mucormycosis and the sensitivity of these microorganisms to antifungal drugs.
4. **Treatment methods**: Evaluate the current methods used to treat mucormycosis, including the use of antifungal drugs and the effect of surgical intervention.
5. **Prognosis**: Analyze the 90 - day and 1 - year survival rates of mucormycosis patients and explore the factors that affect prognosis, such as the use of immunosuppressants, the presence of diabetes, the degree of disease spread, etc.

Through the above analysis, the paper hopes to provide clinical doctors with guiding suggestions on the management of mucormycosis in SOTR and provide basic data for further research. In particular, the study emphasizes the important influence of the immunosuppressive state on the occurrence and development of mucormycosis, and proposes the need for further research to verify these findings and evaluate the potential value of implementing prophylactic antifungal regimens in high - risk SOTR.